Ramucirumab now an option in colorectal and lung cancer

The licensed indications for Cyramza (ramucirumab) have been extended to include the treatment of metastatic colorectal cancer and locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients whose disease has progressed on or after prior therapy with specified chemotherapy regimens.

Previously, the drug was indicated only for the treatment of advanced gastric or gastro-oesophageal junction carcinoma with disease progression after platinum and fluoropyrimidine therapy.

Further information
View Cyramza drug record
Summary of Product Characteristics
Manufacturer: Eli Lilly 

In metastatic colorectal cancer Cyramza is licensed for use in combination with irinotecan, folinic acid and 5-fluorouracil (FOLFIRI) in patients with disease progression on or after treatment with bevacizumab, oxaliplatin and a fluoropyrimidine. 

For patients with locally advanced or metastatic NSCLC it is indicated in combination with docetaxel where disease progression has occurred on or after platinum-based chemotherapy.

Ramucirumab is a receptor-targeted monoclonal antibody that binds specifically to vascular endothelial growth factor (VEGF) receptor 2, blocking binding of VEGF-A, C and D. This inhibits the process of angiogenesis that is required by tumours in order to grow.
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more